Hengrui Medicine’s Innovative Drug Revenue Accounts for Nearly Sixty Percent, BD Restructuring Internationalization Anchor Value

Hengrui Medicine, a leader in the industry that started with generic drugs, has essentially completed the transformation from “combination of imitation and innovation” to ‘innovation-led’. On March 25th, Hengrui Medicine (600276.SH, 01276.HK) released its 2025 annual report. The financial report shows that the annual operating income reached 31.629 billion yuan, a year-on-year growth of 13.02%; the net profit attributable to shareholders of the listed company was 7.711 billion yuan, a year-on-year growth of 21.69%; the net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was 7.413 billion yuan, a year-on-year growth of 20.00%. This growth…